Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2021-01-22 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
2021年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2021 first extraordinary general meeting (临时股东大会) of Yunnan Watson Biotechnology Co., Ltd. It includes voting results for multiple proposals, meeting attendance details, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on shareholder voting outcomes and meeting decisions rather than financial results or management commentary. There is no indication that this is a full annual or interim report, audit report, or earnings release. The document is not a proxy solicitation or investor presentation but a formal announcement of voting results from a shareholder meeting. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and detail support a high confidence in this classification.
2021-01-22 Chinese
关于召开2021年第一次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement about the convening of the 2021 first extraordinary general meeting (临时股东大会) of Yunnan Watson Biotechnology Co., Ltd. It includes information about the meeting date, voting procedures (including online voting), agenda items to be discussed and voted on, registration procedures, and proxy forms. The content focuses on informing shareholders about the meeting logistics and the proposals to be voted on, including issuance of overseas listed foreign shares (H shares) and amendments to company bylaws. There are no financial statements or management discussion and analysis present. The document is not a report of voting results but a notice and detailed information about the upcoming shareholder meeting and the proposals to be considered. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2021-01-18 Chinese
关于修订H股发行后适用的《云南沃森生物技术股份有限公司章程》（修订草案）的公告
Governance Information Classification · 95% confidence The document is a detailed announcement regarding the revision of the company's Articles of Association (公司章程) after the issuance of H shares. It includes legal references to Chinese company law, securities law, and Hong Kong listing rules, and provides a comprehensive comparison of the old and revised articles. The content is focused on governance structure, shareholder rights, share issuance, share transfer restrictions, and other corporate governance matters. There is no indication that this is a full annual report, earnings release, or financial statement. Instead, it is a governance-related document detailing the company's internal rules and regulations. Therefore, the most appropriate classification is Governance Information (CGR). The document length (15,000 characters) and detailed content support this classification with high confidence.
2021-01-07 Chinese
投资决策程序与规则
Governance Information Classification · 100% confidence The document is titled '云南沃森生物技术股份有限公司 投资决策程序与规则' which translates to 'Investment Decision Procedures and Rules' for the company. It is a detailed internal governance document outlining the procedures, rules, and responsibilities related to investment decision-making within the company. It references company law, listing rules, and internal governance structures. There are no financial statements, earnings data, or audit results presented. The document is a governance-related procedural manual rather than a financial report or announcement. It is not an announcement of a report but a substantive internal governance document. Therefore, the most appropriate classification is Governance Information (CGR).
2021-01-06 Chinese
前次募集资金使用情况审核报告
Audit Report / Information Classification · 95% confidence The document is titled as an audit report on the usage of previously raised funds by Yunnan Watson Biotechnology Co., Ltd. It is issued by a certified public accounting firm and includes detailed audit opinions, responsibilities, and extensive financial data on the use and management of raised funds up to September 30, 2020. The document is not a full annual or interim financial report but a specialized audit report focusing on the use of fundraising proceeds, consistent with regulatory requirements from the China Securities Regulatory Commission. It contains audit opinions, detailed financial data, and compliance statements, which aligns with the definition of an Audit Report / Information (AR). The document length is substantial (15,000 characters), and it is not merely an announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is AR with high confidence. 9M 2020
2021-01-06 Chinese
对外担保管理办法
Governance Information Classification · 95% confidence The document is titled '云南沃森生物技术股份有限公司 对外担保管理办法' which translates to 'Yunnan Watson Biotechnology Co., Ltd. External Guarantee Management Measures'. It is a detailed internal policy document outlining the procedures, approvals, and disclosure requirements related to the company's external guarantees and financial guarantees. The content includes references to company law, listing rules, board and shareholder approvals, disclosure obligations, and risk management related to guarantees. There is no indication that this is a financial report, audit report, earnings release, or any form of regulatory filing announcing financial results or changes. It is not a report publication announcement or a certification. Instead, it is a governance-related document detailing internal rules and procedures for managing external guarantees. Therefore, the most appropriate classification is Governance Information (CGR).
2021-01-06 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.